|
gptkbp:instanceOf
|
gptkb:tissue_plasminogen_activator
gptkb:drug
|
|
gptkbp:administrationTimeWindow
|
within 3-4.5 hours of stroke onset
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1987
|
|
gptkbp:ATCCode
|
B01AD02
|
|
gptkbp:bioavailability
|
100% (IV)
|
|
gptkbp:brand
|
gptkb:Activase
gptkb:Actilyse
|
|
gptkbp:CASNumber
|
105857-23-6
|
|
gptkbp:category
|
gptkb:tissue_plasminogen_activator
fibrinolytic drug
|
|
gptkbp:chemicalFormula
|
C2569H3928N746O781S40
|
|
gptkbp:compatibleWith
|
hemorrhagic stroke
|
|
gptkbp:contraindication
|
active internal bleeding
history of hemorrhagic stroke
|
|
gptkbp:cost
|
expensive
|
|
gptkbp:developedBy
|
gptkb:Genentech
|
|
gptkbp:eliminationHalfLife
|
4-6 minutes
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:foundIn
|
hospital formulary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
alteplase
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
converts plasminogen to plasmin
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
59,050 Da
|
|
gptkbp:monitors
|
gptkb:neuroscientist
emergency physician
|
|
gptkbp:origin
|
recombinant DNA technology
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescribes
|
gptkb:physician
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:requiresMonitoring
|
coagulation parameters
neurological status
|
|
gptkbp:riskFactor
|
intracranial hemorrhage
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
bleeding
allergic reaction
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:synonym
|
gptkb:rtPA
recombinant tissue plasminogen activator
|
|
gptkbp:target
|
gptkb:plasminogen
|
|
gptkbp:UNII
|
QGJ20R72FS
|
|
gptkbp:usedFor
|
myocardial infarction
pulmonary embolism
acute ischemic stroke
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Activase
|
|
gptkbp:bfsLayer
|
6
|